University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology , 1441 Eastlake Avenue, Los Angeles, CA, 90033 , USA +1 323 865 3967 ; +1 323 865 0061 ;
Expert Opin Drug Saf. 2014 Jun;13(6):843-51. doi: 10.1517/14740338.2014.915024. Epub 2014 Apr 28.
Panitumumab is a human IgG2 mAb against the EGFR, inhibiting tumor cell proliferation, survival and angiogenesis. It has demonstrated clinical efficacy in metastatic colorectal cancer (CRC) in combination with chemotherapy in first- and second-line settings and as monotherapy in third-line setting. Recently, mutations in the RAS genes have been shown to be predictive of lack of efficacy, panitumumab should be restricted to patients with RAS wild-type (wt) tumors.
This review focuses on main efficacy results of panitumumab in metastatic CRC in first-, second- and third-line settings in combination with chemotherapy or as monotherapy. Additionally, we have covered safety aspects of this agent in these indications, especially in K-RAS and all RAS wt patients. These safety aspects refer to the most common toxicities (i.e., acne-like skin rash, diarrhea and hypomagnesaemia).
Panitumumab adds to the armamentarium of effective agents in the treatment of metastatic CRC. Due to its human origin, panitumumab is a well-tolerated agent with low rates of infusional reactions. Skin toxicity is frequent and should be pre-emptively treated. Other common toxicities related to panitumumab treatment, such as diarrhea and hypomagnesaemia, should be closely monitored to ensure early treatment or substitution.
帕尼单抗是一种针对 EGFR 的人源 IgG2 mAb，可抑制肿瘤细胞增殖、存活和血管生成。它在转移性结直肠癌（CRC）中与化疗联合应用于一线和二线治疗，以及在三线治疗中单药应用均显示出临床疗效。最近，RAS 基因的突变被证明与缺乏疗效有关，因此帕尼单抗应仅限于 RAS 野生型（wt）肿瘤患者。
本综述重点关注帕尼单抗在转移性 CRC 中与化疗联合应用于一线、二线和三线治疗，以及作为单药治疗的主要疗效结果。此外，我们还涵盖了该药物在这些适应证中的安全性方面，特别是在 K-RAS 和所有 RAS wt 患者中。这些安全性方面涉及最常见的毒性（即痤疮样皮疹、腹泻和低镁血症）。
帕尼单抗增加了转移性 CRC 治疗中有效药物的武器库。由于其源自人类，帕尼单抗是一种耐受性良好的药物，输注反应发生率低。皮肤毒性很常见，应预防性治疗。与帕尼单抗治疗相关的其他常见毒性，如腹泻和低镁血症，应密切监测，以确保早期治疗或替代。
